LONDON (Reuters) - Women with mutations in a gene called PALB2 have a one in three chance of developing breast cancer by age 70, according to research that suggests PALB2 is almost as important a risk ...
The SHARON trial is a Phase 1 study designed to evaluate the safety, feasibility, and preliminary efficacy of GO-4, the Company's patented Advanced Redox Modulation regimen consisting of melphalan, ...
Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer. By identifying which mutations affect the function of PALB2, doctors can ...
Hereditary breast cancer results from inherited mutations, primarily in BRCA1 and BRCA2, increasing lifetime cancer risk. Additional genes like TP53, PTEN, PALB2, CHEK2, and ATM also contribute to ...
This podcast will discuss the findings from a phase II trial of gemcitabine, cisplatin and PARP inhibitor therapy in germline BRCA/PALB2 mutant pancreatic cancer and discuss an optimal treatment ...
At the American Society of Clinical Oncology (ASCO) annual meeting, updated data on the use of olaparib (Lynparza) in patients with metastatic breast cancer (MBC) with somatic BRCA1/2 and germline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results